Exact Mass: 441.3243

Exact Mass Matches: 441.3243

Found 114 metabolites which its exact mass value is equals to given mass value 441.3243, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Perindopril erbumine

Perindopril erbumine

C23H43N3O5 (441.3203)


D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Perindopril erbumine is an angiotensin-converting enzyme inhibitor. Perindopril erbumine modulates NF-κB and STAT3 signaling and inhibits glial activation and neuroinflammation. Perindopril erbumine can be used for the research of Chronic Kidney Disease and high blood pressure[1][2][3][4].

   

3-Hydroxy-11Z-octadecenoylcarnitine

(3R)-3-{[(3R,11Z)-3-hydroxyoctadec-11-enoyl]oxy}-4-(trimethylazaniumyl)butanoic acid

C25H47NO5 (441.3454)


3-Hydroxy-11Z-octadecenoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxy-11Z-octadecenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxy-11Z-octadecenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-hydroxy-11Z-octadecenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular 3-hydroxy-11Z-octadecenoylcarnitine is elevated in the blood or plasma of individuals with chronic fatigue syndrome (PMID: 21205027), mitochondrial trifunctional protein deficiency (PMID: 19880769), and psoriasis (PMID: 33391503). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane.  Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. A human metabolite taken as a putative food compound of mammalian origin [HMDB]

   

3-Hydroxy-9Z-octadecenoylcarnitine

(3R)-3-{[(3R,9Z)-3-hydroxyoctadec-9-enoyl]oxy}-4-(trimethylazaniumyl)butanoic acid

C25H47NO5 (441.3454)


3-Hydroxy-9Z-octadecenoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxy-9Z-octadecenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxy-9Z-octadecenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-hydroxy-9Z-octadecenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular 3-hydroxy-9Z-octadecenoylcarnitine is elevated in the blood or plasma of individuals with chronic fatigue syndrome (PMID: 21205027), mitochondrial trifunctional protein deficiency (PMID: 19880769), and psoriasis (PMID: 33391503). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane.  Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. A human metabolite taken as a putative food compound of mammalian origin [HMDB]

   

(9Z)-3-Hydroxyoctadecenoylcarnitine

3-{[(9Z)-3-hydroxyoctadec-9-enoyl]oxy}-4-(trimethylammonio)butanoic acid

C25H47NO5 (441.3454)


(9Z)-3-Hydroxyoctadecenoylcarnitine is an acylcarnitine. More specifically, it is an (9Z)-hydroxyoctadec-9-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9Z)-3-Hydroxyoctadecenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9Z)-3-Hydroxyoctadecenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (9Z)-3-Hydroxyoctadecenoylcarnitine is elevated in the blood or plasma of individuals with chronic fatigue syndrome (PMID: 21205027), mitochondrial trifunctional protein deficiency (PMID: 19880769), and psoriasis (PMID: 33391503). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(12E)-9-Hydroxyoctadecenoylcarnitine

3-[(9-hydroxyoctadec-12-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C25H47NO5 (441.3454)


(12E)-9-Hydroxyoctadecenoylcarnitine is an acylcarnitine. More specifically, it is an (12E)-9-hydroxyoctadec-12-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (12E)-9-Hydroxyoctadecenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (12E)-9-Hydroxyoctadecenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (12E)-9-Hydroxyoctadecenoylcarnitine is elevated in the blood or plasma of individuals with chronic fatigue syndrome (PMID: 21205027), mitochondrial trifunctional protein deficiency (PMID: 19880769), and psoriasis (PMID: 33391503). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(12Z)-10-Hydroxyoctadecenoylcarnitine

3-[(10-hydroxyoctadec-12-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C25H47NO5 (441.3454)


(12Z)-10-Hydroxyoctadecenoylcarnitine is an acylcarnitine. More specifically, it is an (12Z)-10-hydroxyoctadec-12-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (12Z)-10-Hydroxyoctadecenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (12Z)-10-Hydroxyoctadecenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (12Z)-10-Hydroxyoctadecenoylcarnitine is elevated in the blood or plasma of individuals with chronic fatigue syndrome (PMID: 21205027), mitochondrial trifunctional protein deficiency (PMID: 19880769), and psoriasis (PMID: 33391503). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(9Z)-12-Hydroxyoctadec-9-enoylcarnitine

3-[(12-hydroxyoctadec-9-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C25H47NO5 (441.3454)


(9Z)-12-hydroxyoctadec-9-enoylcarnitine is an acylcarnitine. More specifically, it is an (9Z)-12-hydroxyoctadec-9-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9Z)-12-hydroxyoctadec-9-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9Z)-12-hydroxyoctadec-9-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (9Z)-12-hydroxyoctadec-9-enoylcarnitine is elevated in the blood or plasma of individuals with chronic fatigue syndrome (PMID: 21205027), mitochondrial trifunctional protein deficiency (PMID: 19880769), and psoriasis (PMID: 33391503). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Oxooctadecanoylcarnitine

3-[(3-oxooctadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C25H47NO5 (441.3454)


3-oxooctadecanoylcarnitine is an acylcarnitine. More specifically, it is an 3-oxooctadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-oxooctadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-oxooctadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Arachidonoyl Histidine

2-(icosa-5,8,11,14-tetraenamido)-3-(1H-imidazol-5-yl)propanoic acid

C26H39N3O3 (441.2991)


N-arachidonoyl histidine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Arachidonic acid amide of Histidine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Arachidonoyl Histidine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Arachidonoyl Histidine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-Docosahexaenoyl Isoleucine

2-[(1-Hydroxydocosa-4,7,10,13,16,19-hexaen-1-ylidene)amino]-3-methylpentanoate

C28H43NO3 (441.3243)


N-docosahexaenoyl isoleucine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Docosahexaenoyl amide of Isoleucine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Docosahexaenoyl Isoleucine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Docosahexaenoyl Isoleucine is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-Docosahexaenoyl Leucine

2-[(1-Hydroxydocosa-4,7,10,13,16,19-hexaen-1-ylidene)amino]-4-methylpentanoate

C28H43NO3 (441.3243)


N-docosahexaenoyl leucine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Docosahexaenoyl amide of Leucine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Docosahexaenoyl Leucine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Docosahexaenoyl Leucine is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

hydroxyoctadecenoylcarnitine

3,21-dihydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]henicos-5-enoate

C25H47NO5 (441.3454)


   

4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol

5-hydroxy-2,6,15-trimethyl-14-(6-methylhept-5-en-2-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-1(10)-ene-6-carboxylate

C29H45O3 (441.3369)


4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol can be found in a number of food items such as nutmeg, common persimmon, common salsify, and lemon thyme, which makes 4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol a potential biomarker for the consumption of these food products.

   

4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol

5-hydroxy-2,15-dimethyl-14-(6-methyl-5-methylideneheptan-2-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-9-ene-6-carboxylate

C29H45O3 (441.3369)


4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol can be found in a number of food items such as wild celery, common cabbage, watermelon, and chestnut, which makes 4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol a potential biomarker for the consumption of these food products.

   

(20R*,22R*)-N-methyl-5,6,12,13-tetrahydro-3beta,23beta-dihydroxy-5alpha,13beta,17beta,25alpha-veratraman-7,12(14)-dien-6-one|puqienine E

(20R*,22R*)-N-methyl-5,6,12,13-tetrahydro-3beta,23beta-dihydroxy-5alpha,13beta,17beta,25alpha-veratraman-7,12(14)-dien-6-one|puqienine E

C28H43NO3 (441.3243)


   

aspochalasin N

aspochalasin N

C27H39NO4 (441.2879)


   

(24R,6E)-24-ethyl-6-hydroxyimino-cholest-4-en-3-one|(24R,6E)-24-ethylcholest-6-hydroximino-4-en-3-one|(24R,6E)-24-ethylcholest-6-hydroxyimino-4-en-3-one|6E-hydroximino-24-ethylcholest-4-en-3-one

(24R,6E)-24-ethyl-6-hydroxyimino-cholest-4-en-3-one|(24R,6E)-24-ethylcholest-6-hydroximino-4-en-3-one|(24R,6E)-24-ethylcholest-6-hydroxyimino-4-en-3-one|6E-hydroximino-24-ethylcholest-4-en-3-one

C29H47NO2 (441.3607)


   

(2RS,3SR,3RS,3aSR,6SR,6aSR,6bSR,7aRS,11aSR,11bRS)-1,2,3,3a,4,4,5,6,6,6a,6b,7,7,7a,8,11,11a,11b-octadecahydro-7a-methoxy-3,6,10,11b-tetramethylspiro[9H-benzo[a]fluorene-9,2(3H)-furo[3,2-b]pyridin]-3-ol|23-methoxycyclopamine

(2RS,3SR,3RS,3aSR,6SR,6aSR,6bSR,7aRS,11aSR,11bRS)-1,2,3,3a,4,4,5,6,6,6a,6b,7,7,7a,8,11,11a,11b-octadecahydro-7a-methoxy-3,6,10,11b-tetramethylspiro[9H-benzo[a]fluorene-9,2(3H)-furo[3,2-b]pyridin]-3-ol|23-methoxycyclopamine

C28H43NO3 (441.3243)


   

(S,S)-ciliatamide A|ciliatamide A|N-methyl-((S)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-yl)dec-9-enamide

(S,S)-ciliatamide A|ciliatamide A|N-methyl-((S)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-yl)dec-9-enamide

C26H39N3O3 (441.2991)


   

Perindopril Erbumine (Aceon)

Perindopril Erbumine (Aceon)

C23H43N3O5 (441.3203)


   

Lys Pro Val Val

(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2,6-diaminohexanoyl]pyrrolidin-2-yl]formamido}-3-methylbutanamido]-3-methylbutanoic acid

C21H39N5O5 (441.2951)


   

Lys Val Pro Val

(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanoyl]pyrrolidin-2-yl]formamido}-3-methylbutanoic acid

C21H39N5O5 (441.2951)


   

Lys Val Val Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]-3-methylbutanoyl]pyrrolidine-2-carboxylic acid

C21H39N5O5 (441.2951)


   

Pro Lys Val Val

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-pyrrolidin-2-ylformamido]hexanamido]-3-methylbutanamido]-3-methylbutanoic acid

C21H39N5O5 (441.2951)


   

Pro Val Lys Val

(2S)-2-[(2S)-6-amino-2-[(2S)-3-methyl-2-[(2S)-pyrrolidin-2-ylformamido]butanamido]hexanamido]-3-methylbutanoic acid

C21H39N5O5 (441.2951)


   

Pro Val Val Lys

(2S)-6-amino-2-[(2S)-3-methyl-2-[(2S)-3-methyl-2-[(2S)-pyrrolidin-2-ylformamido]butanamido]butanamido]hexanoic acid

C21H39N5O5 (441.2951)


   

Val Lys Pro Val

(2S)-2-{[(2S)-1-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanoyl]pyrrolidin-2-yl]formamido}-3-methylbutanoic acid

C21H39N5O5 (441.2951)


   

Val Lys Val Pro

(2S)-1-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]-3-methylbutanoyl]pyrrolidine-2-carboxylic acid

C21H39N5O5 (441.2951)


   

Val Pro Lys Val

(2S)-2-[(2S)-6-amino-2-{[(2S)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]formamido}hexanamido]-3-methylbutanoic acid

C21H39N5O5 (441.2951)


   

Val Pro Val Lys

(2S)-6-amino-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]formamido}-3-methylbutanamido]hexanoic acid

C21H39N5O5 (441.2951)


   

Val Val Lys Pro

(2S)-1-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-methylbutanamido]hexanoyl]pyrrolidine-2-carboxylic acid

C21H39N5O5 (441.2951)


   

Val Val Pro Lys

(2S)-6-amino-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-methylbutanoyl]pyrrolidin-2-yl]formamido}hexanoic acid

C21H39N5O5 (441.2951)


   

cyclopropyl methyl amide

N-ethyl-9,11,15S-trihydroxy-17-phenyl-18,19,20-trinor-prosta-5Z,13E-dien-1-cyclopropyl methyl amide

C27H39NO4 (441.2879)


   

N-(α-Linolenoyl) Tyrosine

N-(L-tyrosine)-9Z,12Z,15Z-octadecatrienamide

C27H39NO4 (441.2879)


   

Boc-Pro-DVal(NMe)-Val-OMe

Boc-Pro-DVal(NMe)-Val-OMe

C22H39N3O6 (441.2839)


   

N-arachidonoyl histidine

N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-histidine

C26H39N3O3 (441.2991)


   

CAR 18:1;O

3-hydroxyoleoylcarnitine;3-{[(9Z)-3-hydroxyoctadec-9-enoyl]oxy}-4-(trimethylammonio)butanoate;9-cis-3-hydroxyoctadecenoylcarnitine

C25H47NO5 (441.3454)


   

DGLA dopamine

N-(8Z,11Z,14Z-eicosatrienoyl) dopamine

C28H43NO3 (441.3243)


   

LPE O-15:0;O

1-(2-methoxy-tetradecanyl)-sn-glycero-3-phosphoethanolamine

C20H44NO7P (441.2855)


   

[1,1-Bis(hydroxymethyl)-3-(4-octylphenyl)propyl]carbamic acid Phenylmethyl Ester

[1,1-Bis(hydroxymethyl)-3-(4-octylphenyl)propyl]carbamic acid Phenylmethyl Ester

C27H39NO4 (441.2879)


   

PHENOL, 2-(2H-BENZOTRIAZOL-2-YL)-6-(1-METHYL-1-PHENYLETHYL)-4-(1,1,3,3-TETRAMETHYLBUTYL)-

PHENOL, 2-(2H-BENZOTRIAZOL-2-YL)-6-(1-METHYL-1-PHENYLETHYL)-4-(1,1,3,3-TETRAMETHYLBUTYL)-

C29H35N3O (441.278)


   

2-(dimethylamino)ethyl 2-methylprop-2-enoate,2-ethylhexyl prop-2-enoate,methyl 2-methylprop-2-enoate

2-(dimethylamino)ethyl 2-methylprop-2-enoate,2-ethylhexyl prop-2-enoate,methyl 2-methylprop-2-enoate

C24H43NO6 (441.309)


   

DOWEX(R) 550A OH

DOWEX(R) 550A OH

C31H39NO (441.3031)


   

Ciliatamide A

Ciliatamide A

C26H39N3O3 (441.2991)


A lipopeptide that contains N-methylphenylalanine and lysine as the amino acid residues linked to a dec-9-enoyl moiety via an amide linkage (the R,R stereoisomer). It is isolated from the deep sea sponge Aaptos ciliata and exhibits antileishmanial activity.

   

4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol

5-hydroxy-2,6,15-trimethyl-14-(6-methylhept-5-en-2-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-1(10)-ene-6-carboxylate

C29H45O3 (441.3369)


4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol can be found in a number of food items such as nutmeg, common persimmon, common salsify, and lemon thyme, which makes 4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol a potential biomarker for the consumption of these food products. 4α-carboxy-4β-methyl-5α-cholesta-8,24-dien-3β-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4α-carboxy-4β-methyl-5α-cholesta-8,24-dien-3β-ol can be found in a number of food items such as nutmeg, common persimmon, common salsify, and lemon thyme, which makes 4α-carboxy-4β-methyl-5α-cholesta-8,24-dien-3β-ol a potential biomarker for the consumption of these food products.

   

4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol

5-hydroxy-2,15-dimethyl-14-(6-methyl-5-methylideneheptan-2-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-9-ene-6-carboxylate

C29H45O3 (441.3369)


4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol can be found in a number of food items such as wild celery, common cabbage, watermelon, and chestnut, which makes 4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol a potential biomarker for the consumption of these food products. 4α-carboxy-ergosta-7,24(241)-dien-3β-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4α-carboxy-ergosta-7,24(241)-dien-3β-ol can be found in a number of food items such as wild celery, common cabbage, watermelon, and chestnut, which makes 4α-carboxy-ergosta-7,24(241)-dien-3β-ol a potential biomarker for the consumption of these food products.

   

(4S)-4-[(Z)-3-hydroxyoctadec-9-enoyl]oxy-4-(trimethylazaniumyl)butanoate

(4S)-4-[(Z)-3-hydroxyoctadec-9-enoyl]oxy-4-(trimethylazaniumyl)butanoate

C25H47NO5 (441.3454)


   

4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol

3-Hydroxy-4,10,13-trimethyl-17-(6-methylhept-5-en-2-yl)-1,2,3,5,6,7,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-4-carboxylate

C29H45O3- (441.3369)


4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol can be found in a number of food items such as nutmeg, common persimmon, common salsify, and lemon thyme, which makes 4alpha-carboxy-4beta-methyl-5alpha-cholesta-8,24-dien-3beta-ol a potential biomarker for the consumption of these food products.

   

4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol

3-hydroxy-10,13-dimethyl-17-(6-methyl-5-methylideneheptan-2-yl)-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-4-carboxylate

C29H45O3- (441.3369)


4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol can be found in a number of food items such as wild celery, common cabbage, watermelon, and chestnut, which makes 4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol a potential biomarker for the consumption of these food products.

   

4beta-Methylzymosterol-4alpha-carboxylate

4beta-Methylzymosterol-4alpha-carboxylate

C29H45O3- (441.3369)


A steroid acid anion that is the conjugate base of 4beta-methylzymosterol-4alpha-carboxylic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol

4alpha-carboxy-ergosta-7,24(241)-dien-3beta-ol

C29H45O3- (441.3369)


   

4beta-Carboxy-4alpha-methyl-5alpha-cholesta-8,24-dien-3beta-ol

4beta-Carboxy-4alpha-methyl-5alpha-cholesta-8,24-dien-3beta-ol

C29H45O3- (441.3369)


   

3-Oxo-24-ethyl-cholest-4-en-26-oate

3-Oxo-24-ethyl-cholest-4-en-26-oate

C29H45O3- (441.3369)


   

4alpha-carboxy-ergosta-8,25(27)-dienol

4alpha-carboxy-ergosta-8,25(27)-dienol

C29H45O3- (441.3369)


   

3-Hydroxy-11Z-octadecenoylcarnitine

3-Hydroxy-11Z-octadecenoylcarnitine

C25H47NO5 (441.3454)


   

3-Oxooctadecanoylcarnitine

3-Oxooctadecanoylcarnitine

C25H47NO5 (441.3454)


   

3-Hydroxy-9(Z)-octadecenoylcarnitine

3-Hydroxy-9(Z)-octadecenoylcarnitine

C25H47NO5 (441.3454)


   

(E)-3,21-dihydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]henicos-5-enoate

(E)-3,21-dihydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]henicos-5-enoate

C25H47NO5 (441.3454)


   

N-Docosahexaenoyl Isoleucine

N-Docosahexaenoyl Isoleucine

C28H43NO3 (441.3243)


   

(12E)-9-Hydroxyoctadecenoylcarnitine

(12E)-9-Hydroxyoctadecenoylcarnitine

C25H47NO5 (441.3454)


   

(12Z)-10-Hydroxyoctadecenoylcarnitine

(12Z)-10-Hydroxyoctadecenoylcarnitine

C25H47NO5 (441.3454)


   

(9Z)-12-Hydroxyoctadec-9-enoylcarnitine

(9Z)-12-Hydroxyoctadec-9-enoylcarnitine

C25H47NO5 (441.3454)


   

2-[[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid

2-[[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid

C26H39N3O3 (441.2991)


   

2-[[(4E,7E,10E,13E,16E,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]-4-methylpentanoic acid

2-[[(4E,7E,10E,13E,16E,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]-4-methylpentanoic acid

C28H43NO3 (441.3243)


   

n-(alpha-Linolenoyl) tyrosine

n-(alpha-Linolenoyl) tyrosine

C27H39NO4 (441.2879)


   

(15Z,18Z,21Z,24Z,27Z)-triacontapentaenoate

(15Z,18Z,21Z,24Z,27Z)-triacontapentaenoate

C30H49O2- (441.3732)


A polyunsaturated fatty acid anion that is the conjugate base of (15Z,18Z,21Z,24Z,27Z)-triacontapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(12Z,15Z,18Z,21Z,24Z)-triacontapentaenoate

(12Z,15Z,18Z,21Z,24Z)-triacontapentaenoate

C30H49O2- (441.3732)


A polyunsaturated fatty acid anion that is the conjugate base of (12Z,15Z,18Z,21Z,24Z)-triacontapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(2E)-19-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]nonadec-2-enoate

(2E)-19-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]nonadec-2-enoate

C25H45O6- (441.3216)


   

(4S)-4-[(Z)-3-hydroxyoctadec-11-enoyl]oxy-4-(trimethylazaniumyl)butanoate

(4S)-4-[(Z)-3-hydroxyoctadec-11-enoyl]oxy-4-(trimethylazaniumyl)butanoate

C25H47NO5 (441.3454)


   

(E,18R)-18-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxynonadec-2-enoate

(E,18R)-18-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxynonadec-2-enoate

C25H45O6- (441.3216)


   

NAGly 12:0/11:0

NAGly 12:0/11:0

C25H47NO5 (441.3454)


   

NAGly 10:0/13:0

NAGly 10:0/13:0

C25H47NO5 (441.3454)


   

NAGly 13:0/10:0

NAGly 13:0/10:0

C25H47NO5 (441.3454)


   

NAGly 11:0/12:0

NAGly 11:0/12:0

C25H47NO5 (441.3454)


   

Cer 9:0;3O/16:2;(2OH)

Cer 9:0;3O/16:2;(2OH)

C25H47NO5 (441.3454)


   

Cer 13:1;3O/12:1;(2OH)

Cer 13:1;3O/12:1;(2OH)

C25H47NO5 (441.3454)


   

Cer 12:1;3O/13:1;(2OH)

Cer 12:1;3O/13:1;(2OH)

C25H47NO5 (441.3454)


   

lysoDGTS 14:2

lysoDGTS 14:2

C24H43NO6 (441.309)


   

(9Z)-3-hydroxyoctadecenoylcarnitine

(9Z)-3-hydroxyoctadecenoylcarnitine

C25H47NO5 (441.3454)


An O-acylcarnitine having (9Z)-3-hydroxyoctadecenoyl as the acyl substituent.

   

Dihomo-gamma-linolenoyl dopamine

Dihomo-gamma-linolenoyl dopamine

C28H43NO3 (441.3243)


   

ascr#33(1-)

ascr#33(1-)

C25H45O6 (441.3216)


Conjugate base of ascr#33

   

triacontapentaenoate

triacontapentaenoate

C30H49O2 (441.3732)


A polyunsaturated fatty acid anion that is the conjugate base of triacontapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

O-(hydroxyoctadecenoyl)carnitine

O-(hydroxyoctadecenoyl)carnitine

C25H47NO5 (441.3454)


An O-acylcarnitine having hydroxyoctadecenoyl as the acyl group in which the position of the double bond and hydroxy group are unspecified.

   

O-hydroxyoctadecenoyl-L-carnitine

O-hydroxyoctadecenoyl-L-carnitine

C25H47NO5 (441.3454)


An O-acyl-L-carnitine that is L-carnitine having a hydroxyoctadecenoyl group as the acyl substituent in which the position of the double bond and the hydroxy group is unspecified.

   

oscr#33(1-)

oscr#33(1-)

C25H45O6 (441.3216)


A hydroxy fatty acid ascaroside anion that is the conjugate base of oscr#33, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

CarE(18:1)

CarE(18:1(1+O))

C25H47NO5 (441.3454)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   
   
   
   

NA-Cys 22:1(11Z)

NA-Cys 22:1(11Z)

C25H47NO3S (441.3276)


   

NA-Dopamine 20:3(8Z,11Z,14Z)

NA-Dopamine 20:3(8Z,11Z,14Z)

C28H43NO3 (441.3243)


   
   

NA-His 20:4(5Z,8Z,11Z,14Z)

NA-His 20:4(5Z,8Z,11Z,14Z)

C26H39N3O3 (441.2991)


   

NA-Ile 22:6(4Z,7Z,10Z,13Z,16Z,19Z)

NA-Ile 22:6(4Z,7Z,10Z,13Z,16Z,19Z)

C28H43NO3 (441.3243)


   

NA-Leu 22:6(4Z,7Z,10Z,13Z,16Z,19Z)

NA-Leu 22:6(4Z,7Z,10Z,13Z,16Z,19Z)

C28H43NO3 (441.3243)


   

NA-Met 20:1(11Z)

NA-Met 20:1(11Z)

C25H47NO3S (441.3276)


   

NA-Tyr 18:3(6Z,9Z,12Z)

NA-Tyr 18:3(6Z,9Z,12Z)

C27H39NO4 (441.2879)


   

NA-Tyr 18:3(9Z,12Z,15Z)

NA-Tyr 18:3(9Z,12Z,15Z)

C27H39NO4 (441.2879)


   

CAR 18:1(9Z);3OH

CAR 18:1(9Z);3OH

C25H47NO5 (441.3454)


   
   
   
   

ST 25:4;O2;Gly

ST 25:4;O2;Gly

C27H39NO4 (441.2879)


   

(3s,3ar,4s,6as,14r,15ar)-1-hydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-14-(2-oxopropyl)-3h,3ah,4h,6ah,9h,10h,11h,13h,14h-cycloundeca[d]isoindole-12,15-dione

(3s,3ar,4s,6as,14r,15ar)-1-hydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-14-(2-oxopropyl)-3h,3ah,4h,6ah,9h,10h,11h,13h,14h-cycloundeca[d]isoindole-12,15-dione

C27H39NO4 (441.2879)


   

(6e)-1-[(5s)-2,4-dihydroxy-5-[(s)-hydroxy(phenyl)methyl]-5h-pyrrol-3-yl]-4,6,8,10-tetramethyldodec-6-en-1-one

(6e)-1-[(5s)-2,4-dihydroxy-5-[(s)-hydroxy(phenyl)methyl]-5h-pyrrol-3-yl]-4,6,8,10-tetramethyldodec-6-en-1-one

C27H39NO4 (441.2879)


   

(3e,5e)-14-hydroxy-3,7,11-trimethyltetradeca-3,5-dien-1-yl 2-(hydroxymethyl)-1h-indole-3-carboxylate

(3e,5e)-14-hydroxy-3,7,11-trimethyltetradeca-3,5-dien-1-yl 2-(hydroxymethyl)-1h-indole-3-carboxylate

C27H39NO4 (441.2879)


   

(2s)-n-[(3s)-2-hydroxy-4,5,6,7-tetrahydro-3h-azepin-3-yl]-2-(n-methyldec-9-enamido)-3-phenylpropanimidic acid

(2s)-n-[(3s)-2-hydroxy-4,5,6,7-tetrahydro-3h-azepin-3-yl]-2-(n-methyldec-9-enamido)-3-phenylpropanimidic acid

C26H39N3O3 (441.2991)


   

1-hydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-14-(2-oxopropyl)-3h,3ah,4h,6ah,9h,10h,11h,13h,14h-cycloundeca[d]isoindole-12,15-dione

1-hydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-14-(2-oxopropyl)-3h,3ah,4h,6ah,9h,10h,11h,13h,14h-cycloundeca[d]isoindole-12,15-dione

C27H39NO4 (441.2879)


   

14-hydroxy-3,7,11-trimethyltetradeca-3,5-dien-1-yl 2-(hydroxymethyl)-1h-indole-3-carboxylate

14-hydroxy-3,7,11-trimethyltetradeca-3,5-dien-1-yl 2-(hydroxymethyl)-1h-indole-3-carboxylate

C27H39NO4 (441.2879)


   

(2r)-n-[(3r)-2-hydroxy-4,5,6,7-tetrahydro-3h-azepin-3-yl]-2-(n-methyldec-9-enamido)-3-phenylpropanimidic acid

(2r)-n-[(3r)-2-hydroxy-4,5,6,7-tetrahydro-3h-azepin-3-yl]-2-(n-methyldec-9-enamido)-3-phenylpropanimidic acid

C26H39N3O3 (441.2991)


   

1-{2,4-dihydroxy-5-[hydroxy(phenyl)methyl]-5h-pyrrol-3-yl}-4,6,8,10-tetramethyldodec-6-en-1-one

1-{2,4-dihydroxy-5-[hydroxy(phenyl)methyl]-5h-pyrrol-3-yl}-4,6,8,10-tetramethyldodec-6-en-1-one

C27H39NO4 (441.2879)


   

n-(2-hydroxy-4,5,6,7-tetrahydro-3h-azepin-3-yl)-2-(n-methyldec-9-enamido)-3-phenylpropanimidic acid

n-(2-hydroxy-4,5,6,7-tetrahydro-3h-azepin-3-yl)-2-(n-methyldec-9-enamido)-3-phenylpropanimidic acid

C26H39N3O3 (441.2991)


   

(4s)-4-{[(9z)-3-hydroxyoctadec-9-enoyl]oxy}-4-(trimethylammonio)butanoate

(4s)-4-{[(9z)-3-hydroxyoctadec-9-enoyl]oxy}-4-(trimethylammonio)butanoate

C25H47NO5 (441.3454)